Prior to GLIVEC, the prognosis for patients with gastrointestinal stromal tumour (GIST) was poor. Tumour recurrence often followed surgical resection for primary disease. In advanced disease, there were no effective treatment options, and survival averaged about 1 year.1,2

Data show 3 years of adjuvant GLIVEC is significantly reducing the risk of tumour recurrence following surgery for patients with KIT+ GIST, extending their lives with a 92% overall survival rate at 5 years.3 And, in the treatment of advanced KIT+ GIST, GLIVEC is extending the lives of patients for a median of nearly 5 years, even in the face of disease progression.4

Recently Resected KIT+ GIST

References: 1. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99(1):42-47. 2. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-58. 3. Glivec® (imatinib) summary of product characteristics. West Sussex, UK: Novartis Europharm Limited; 2016. 4. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620-625.